YTHDF2 inhibition potentiates radiotherapy antitumor efficacy

Liangliang Wang,Xiaoyang Dou,Shijie Chen,Xianbin Yu,Xiaona Huang,Linda Zhang,Yantao Chen,Jiaai Wang,Kaiting Yang,Jason Bugno,Sean Pitroda,Xingchen Ding,Andras Piffko,Wei Si,Chao Chen,Hualiang Jiang,Bing Zhou,Cheng Luo,Hua Laura Liang,Chuan He,Steven J. Chmura,Ralph R. Weichselbaum

DOI: https://doi.org/10.1016/j.ccell.2023.04.019

IF: 50.3

2023-05-01

Cancer Cell

Abstract:RNA N⁶-methyladenosine (m⁶A) modification is implicated in cancer progression. However, the impact of m⁶A on the antitumor effects of radiotherapy and the related mechanisms are unknown. Here we show that ionizing radiation (IR) induces immunosuppressive myeloid-derived suppressor cell (MDSC) expansion and YTHDF2 expression in both murine models and humans. Following IR, loss of Ythdf2 in myeloid cells augments antitumor immunity and overcomes tumor radioresistance by altering MDSC differentiation and inhibiting MDSC infiltration and suppressive function. The remodeling of the landscape of MDSC populations by local IR is reversed by Ythdf2 deficiency. IR-induced YTHDF2 expression relies on NF-κB signaling; YTHDF2 in turn leads to NF-κB activation by directly binding and degrading transcripts encoding negative regulators of NF-κB signaling, resulting in an IR-YTHDF2-NF-κB circuit. Pharmacological inhibition of YTHDF2 overcomes MDSC-induced immunosuppression and improves combined IR and/or anti-PD-L1 treatment. Thus, YTHDF2 is a promising target to improve radiotherapy (RT) and RT/immunotherapy combinations.

oncology,cell biology